The p53 tumour suppressor protein is a transcriptional actip53, monomeric variants were not able to induce vator, which can induce cell cycle arrest and apoptosis.
Introduction
The p53 tumour suppressor gene is one of the most important targets for mutations in human malignancies. Upon cellular stress, such as DNA damage or hypoxia, p53 protein accumulates 1, 2 and arrests the cell cycle or triggers programmed cell death, apoptosis. This mechanism is thought to prevent the acquisition and propagation of genetic aberrations. 3 p53 is a transcription factor and its domain structure has been well defined. The molecule consists of an amino-terminal transactivation domain, a central DNA binding domain and a carboxyterminal oligomerisation domain. [4] [5] [6] Wild-type p53 transactivates target genes by binding to specific DNA response elements. [7] [8] [9] Response elements have been found in the p21/waf1/cip1, [10] [11] [12] mdm2, 13, 14 Gadd45, 15 cyclin G, 16 bax 17 and IGFBP-3 18 genes. Mutant p53 variants have been described which discriminate in their transactivation between individual p53 response elements. [19] [20] [21] Distinct classes of p53-responsive promoters may exist which differ in extent of induction and their sensitivity towards p53 mutants.
Regulation of p53 function is often mediated by the carboxy-terminal domain of the protein. Several phosphorylation sites have been detected in this region 22, 23 and small peptides or antibodies which bind to this
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Received 17 March 1998; accepted 2 July 1998 domain can regulate p53 activity. 24, 25 Recently, acetylation of a peptide consisting of the amino acids 364-393 from wt p53 was shown. 26 Deletion of the last 30 amino acids strongly stimulates p53 to bind to its DNA response element, suggesting the removal of a negatively regulating function. The redox/repair protein Ref-1 was shown to activate p53 by both redox-dependent and independent means acting through the carboxy-terminal region of p53. 27 These observations support the model of allosteric activation of p53 28, 29 in response to genotoxic stress situations.
In addition to its sequence-specific transactivation function, p53 can also suppress transcription from cellular and viral promoters, 30, 31 in particular those containing TATA elements. 32 Although transcriptional repression might contribute to some p53-mediated phenotypes, 33 it is the transcriptional activation of target genes, in particular of p21/Waf1/Cip1, which is closely correlated with the growth-inhibitory effect of p53. [34] [35] [36] Under special conditions p53 can induce apoptosis in the absence of transcriptional activation of target genes, [37] [38] [39] but many cellular systems require transcriptionally active, wildtype p53 for a full apoptotic response. 40, 41 The divergent observations suggest that transcription-dependent and -independent mechanisms exist, and that their relative importance varies between cell types and is dependent upon experimental conditions.
It has been suggested that the heterodimerisation between mutant and wild-type p53 is responsible for the dominant-negative effect which is exerted by the mutant form over the wild-type. 42 For this reason strategies have been devised which aim at the reactivation of wild-type p53 through interference with the oligomerisation process and the release of wild-type from mutant p53. 43 We have focused our attention on the function of monomeric p53 variants which lack the oligomerisation domain and which are unable to complex with mutant forms. These variants should elude the dominant-negative influence of mutant p53 and might be useful in a gene therapeutic setting.
We investigated the effects of p53 truncation mutants on the transactivation of transfected reporter gene constructs and on endogenous genes and have measured the induction of apoptosis in HeLa and SKBR3 cells. We found that the variant p53⌬326 retains a diminished transactivation potential when measured on PG13 or mdm2 promoter luciferase constructs; the further truncated variant p53⌬300 was mostly inactive. In contrast to wild-type p53, p53⌬326 was unable to induce apoptosis in the transiently transfected cells which might be correlated with its inability to induce the bax gene. We also derived SKBR3 and Saos2 cell clones in which the expression of p53 or p53⌬326 were subjected to tetracycline control. Consistent with the results obtained in the transiently transfected cells, p53⌬326 did not induce apoptosis.
Results
Transactivation potential of p53, p53⌬326 and p53⌬300 in transiently transfected HeLa and SKBR3 cells We derived p53 variants in which the carboxy-terminal 67 amino acids, p53⌬326, or 93 amino acids, p53⌬300, were deleted ( Figure 1a) . p53⌬326 retains the main nuclear localisation sequences, 44 p53⌬300 does not. Transactivation potentials of the constructs were tested in transiently transfected HeLa, human cervical carcinoma cells and SKBR3, human mammary carcinoma cells. HeLa cells are transformed by HPV, leading to a rapid degradation of endogenous wt p53 by the HPV E6 protein. SKBR3 cells express the p53His175 mutant. Three reporter plasmids with p53 response elements in their promoter regions were employed. PG13-luc is a construct in which multimerised p53 binding sites have been assembled into an artificial promoter region; 7 mdm2-luc utilises the promoter region of the mouse mdm2 gene 45 and bax-luc the promoter region of the human bax gene 17 to direct the transcription of the luciferase gene. We also investigated the dose-response and compared the luciferase activities obtained upon transfection of 1 or 5 g of the p53 expression plasmids. The luciferase values obtained in the absence and presence of cotransfected p53 expression plasmids are shown in Figure 1 .
p53⌬326 retains specific transactivation activity, although it is less active than wild-type p53. p53⌬326 induces the PG13-luc gene about 20-fold in SKBR3 cells, as compared with a 40-fold induction by wild-type p53 (Figure 1b, left panel) . A 20-fold induction by p53⌬326 was also observed in HeLa cells, where wild-type p53 caused an about 150-fold induction (Figure 1b , right panel). p53⌬300 was unable to induce transcription of PG13-luc significantly in both cell lines. The situation was similar in SKBR3 cells transfected with the mdm2-luc gene. Wild-type p53 caused a strong induction (45-fold), p53⌬326 a weak induction (10-fold) and p53⌬300 no induction ( Figure 1c, left panel) . In contrast to these results, p53⌬300 was able to induce mdm2-luc about fivefold in HeLa cells (Figure 1c, right panel) . The bax-luc reporter gene was induced three-to five-fold by wildtype p53 in SKBR3 or in HeLa cells, the two deletion mutants had no activity (Figure 1d ). The induction of luciferase activity was p53 dose dependent. Higher levels of the deletion mutants result in higher luciferase activity. Higher levels of wild-type p53 in SKBR3 cells were less efficient to activate transcription when compared with lower levels. This dose-response effect was observed with all three reporter genes used although the overall transactivation efficiency among them varied widely.
The DNA binding efficiency of p53⌬326 is reduced when compared with wild-type p53 We compared the in vitro DNA binding efficiency of wild-type p53 and the monomeric p53⌬326 in mobility shift assays (Figure 2 ). The p53 DNA binding sequence BC 28 was used as a radioactive probe. Nuclear extracts were prepared from SKBR3 cells transiently transfected with the wild-type p53 gene. Strong, specific DNA-binding of wild-type p53 was observed (Figure 2a, lane 3) . The presence of the monoclonal antibody PAb1801 resulted in a supershifted complex (lane 4). No or only weak specific DNA binding was observed when nuclear extracts from SKBR3 cells transfected with p53⌬326 were introduced into the bandshift assay (lane 5). A specific protein DNA complex, however, was detected when the monoclonal antibody PAb1801 was added to the binding reaction (lane 6). Specificity of p53 binding was shown by oligonucleotide competition with a 50-fold molar excess of unlabeled DNA (lane 7). The low efficiency of p53⌬326 DNA binding when compared with wild-type p53 is not attributable to expression levels. Western blot analysis showed that higher levels of p53⌬326 than wildtype p53 are expressed in the transfected SKBR3 cells. In contrast to p53⌬326, we were not able to detect specific DNA binding by p53⌬300 (data not shown).
SKBR3 cells express the mutant p53His175. This p53 variant is unable to bind specifically to DNA in the absence or presence of PAb1801 (Figure 2a, lanes 1 and  2) . The DNA binding activity of transfected wild-type p53 was not inhibited by the endogenously expressed mutant p53His175 (Figure 2a, lane 3) .
The DNA binding efficiency of p53⌬326 and the influence of the antibody PAb1801 were further analysed using bacterially expressed, recombinant p53 protein (Figure 2b ). Equal amounts of recombinant protein were incubated with the radioactive oligonucleotide BC in the absence (Figure 2b, lanes 1-3) or in the presence (lanes 4-6) of the monoclonal antibody. After 30 min an aliquot containing 100 ng of the recombinant protein of the binding reactions was loaded on to the acrylamide gel ( Figure 2b, lanes 1 and 4) . A 200-fold excess of unlabeled DNA probe was added to the binding reactions. After incubation for 1 min (Figure 2b , lanes 2 and 5) or 5 min (lanes 3 and 6) aliquots of the binding reactions were loaded on to the gel. Addition of the monoclonal antibody resulted in a stabilisation of protein-DNA complexes of p53⌬326. In the absence of the antibody the labeled DNA probe was displaced rapidly by the competing nonradioactive probe (Figure 2b , lanes 2 and 3). In the presence of PAb1801 the dissociation from the labeled DNA was delayed. In contrast to the p53⌬326 derived from nuclear extracts of the transfected cells, recombinant p53⌬326 bound to the DNA probe efficiently even in the absence of the antibody. This is possibly due to the higher protein concentration present in the binding reaction.
The in vitro DNA binding efficiency of p53⌬326 is reduced when compared with wild-type p53, but can be increased by addition of the monoclonal antibody PAb1801 to the binding reactions. We suggest that the decreased DNA binding potential of p53⌬326 is probably responsible for the decreased transactivation potential of this monomeric variant.
Wild-type p53, but not p53⌬326 induces apoptosis in transiently transfected HeLa or SKBR3 cells We studied the effects of wild-type p53 on the survival of transiently transfected HeLa or SKBR3 cells and compared them with those of p53⌬326. For this purpose, the cells were transfected, fixed after different intervals following transfection and incubated with the monoclonal p53-specific antibody PAb1801 and a FITC-conjugated secondary antibody ( Figure 3 , a-d).
Immunofluorescence microscopy of HeLa cells transfected with wild-type p53 40 h after transfection showed strong expression of p53 restricted to nuclei ( Figure 3a , green color). About 50% of the nuclei exhibit the characteristic morphology of apoptosis (arrows). The induction of apoptosis by wild-type p53 was counteracted by the cotransfection of the bcl-2 gene (Figure 3b ). p53⌬326 and, as a control, mutant p53His175 were not able to induce apoptosis in HeLa cells (Figure 3c and d) . Cotransfection of the bcl-2 gene did not affect the viability of transfected cells (not shown). Induction of apoptosis by wild-type p53, but not by p53⌬326 was also observed in transiently transfected SKBR3 cells (data not shown).
Figure 3 p53 expression and induction of apoptosis in transiently trans
We quantified the appearance of apoptotic cells as a function of time after transfection with the p53 variants (Figure 3e) . No apoptotic cells were detected within the p53 expressing cells for 24 h. Forty-eight hours after transfection, about 50% of the wild-type p53-expressing cells were apoptotic. Almost all cells were dead within 64 h. Only a few dead cells were found in the populations transfected with and expressing p53⌬326 or p53His175. The same is true for cells transfected with p53⌬300 (not shown). The results show that the carboxy-terminally truncated variants, similar to the tumour cell-derived p53His175, are deficient in the induction of apoptosis in HeLa or SKBR3 cells.
Induction of conditional, tetracycline-regulated p53 gene constructs in Saos2 and SKBR3 To study the induction of apoptosis by wild-type p53 and p53⌬326 independently from the process of transfection, we derived expression vectors for these p53 variants in which transcription has been subjected to the control of tetracycline. The tetracycline-inducible wild-type p53 and p53⌬326 constructs were stably introduced into Saos2, p53-negative human osteosarcoma cells, and SKBR3 cells. Stably transfected cell clones were grown in medium containing tetracycline. For p53 induction, tetracycline was removed. 46 We followed the induction of p53 expression and the induction of apoptosis as a function of time after tetracycline removal from the cell culture medium (Figure 4 ). At 0, 24 and 48 h the cells were fixed and incubated with PAb1801 and FITC-conjugated second antibody to visualise p53 expression (left panels) and propidium iodide to visualise DNA (right panels). Each pair in Figure 4a Saos2 population was in accordance with the nonsynchronous onset of apoptosis. Delayed induction of p53 resulted in a delayed onset of apoptosis (Figure 4c ). Individual cells have completely lost the ability to induce p53, and survive even extended times of tetracycline withdrawal.
Expression of p53-dependent cellular genes in tetracycline-inducible cell lines At least three parameters have been recognised to be important in the quantitative regulation of p53-dependent transcription: the cellular concentration of p53, the activation status of p53 29 and the sequence and sequence context of the response element in the promoters of p53 target genes. 19, 41 Since these parameters could contribute to the results that we have obtained in the analysis of p53 mutants in our transient transfection experiments, we also investigated the induction of endogenous, p53-dependent genes in our stably transfected, conditional cell lines.
P21/waf1/cip1 is a crucial target gene of p53. P21 mediates the p53 cell cycle arrest through inhibition of the activities of cyclin-dependent kinases. We measured the induction of p21 expression by immunofluorescence in SKBR3 cells expressing wild-type p53 or p53⌬326 upon tetracycline withdrawal (Figure 5a ). The cells were stained with a p53-specific antibody (red fluorescence) and a p21-specific antibody (green fluorescence). Induction of the endogenous p21 gene was only observed in wild-type p53 expressing cells, but not in cells expressing 
Figure 5 Regulation of endogenous target genes by induction of p53 expression in Saos2 and SKBR3 cells. (a) Immunofluorescence analysis of p53 and p21 expression in tetracycline-regulated SKBR3 cells, expressing wild-type p53 or p53⌬326. Cells were fixed 24 h after induction, stained for p53 (Cy3-conjugated secondary antibody, red) and p21 (FITC-conjugated secondary antibody, green) and viewed under two different wavelengths. Uninduced cells showed only background staining of p53 due to the endogenous mutant p53, but no p21 staining (not shown). (b) Analysis of p53 and p21 mRNA levels by RT-PCR. The transcription of p53 and p21 in stable cell clones of Saos2 and SKBR3 cells was measured. Uninduced cells (+tet) or cells induced for the indicated times were collected, mRNA was prepared and the reverse transcription and PCR recations were carried out as described in Materials and methods. The PCR products were visualised upon gel electrophoresis. (*) ␤-Actin specific band (288 bp) was used as an endogenous standard in each PCR reaction. The sizes of the specific bands are indicated by the arrows; 1 kb ladder (Gibco) was used as a marker (not shown). (c) Quantitative analysis of the p53-induced mRNA levels. The mRNA levels of p53, p21, mdm2, Gadd45, bax and IGF-1R in the four stable cell clones were measured in RT-PCR reactions. Signal strength was calculated after scanning and quantification of the bands using ImageQuant (Molecular Dynamics

p53⌬326 or in uninduced cells (not shown). Similar results were obtained with two Saos2 cell clones (data not shown).
We examined the expression of additional p53 target genes in inducible Saos2 or SKBR3 cell lines by RT-PCR analysis. Saos2 were induced for 12 and 24 h and SKBR3 cells for longer, 24 and 48 h. RT-PCR reactions were performed to quantify the transcription of the p53, p21/waf1/cip1, bax, mdm2, Gadd45 and IGF-1R genes. Endogenous ␤-actin mRNA served as an internal standard for the RT reaction and efficiency of the PCR amplifications. Figure 5b shows the results of PCR amplifications in which p53-and p21-specific primers have been introduced. The PCR signals were quantified and the expression levels of p53, p21, mdm2, Gadd45, bax and IGF-1R mRNA are indicated in Figure 5c .
The transcription of the p53 gene was low in all four cell clones as long as the cells were grown in tetracycline. These results were confirmed in Northern blot, Western blot and immunofluorescence analysis (data not shown). p21 mRNA was induced in Saos2 and SKBR3 cells by wild-type p53, but not by p53⌬326. p21 expression is not exclusively controlled by p53 47 and a signal is detectable in the absence of p53 (+tetracycline). Bax mRNA was induced in SKBR3 and Saos2 cells after expression of wild-type p53, but not p53⌬326. The monomeric p53 mutant is not able to stimulate transcription of this apoptosis inducing target gene. Similar observations were made concerning the transcription of the mdm2 gene in both cell lines, induction by wild-type p53, no effect by p53⌬326. Gadd45 mRNA was induced by wild-type p53 in SKBR3 and Saos2 cells. High constitutive levels were present in p53⌬326 Saos2 cells.
It has been reported that the IGF-1 receptor gene transcription is repressed by p53, a mechanism which might neutralise the apoptosis inhibiting action of IGF-1 receptor activation. 48, 49 We measured IGF-1 receptor mRNA upon induction of p53 or p53⌬326 and did not observe significant changes in the RT-PCR signals. The reported repression might be cell line dependent. Repression of the IGF-1R is not essential for p53-induced apoptosis in Saos2 and SKBR3 cells.
Discussion
We have evaluated the potential of two carboxy-terminal deletion mutants of p53, p53⌬326 and p53⌬300 with respect to their ability to transactivate responsive genes and to induce apoptosis. These variants are lacking the carboxy-terminal regulatory and oligomerisation domain and act as monomers. We found that the two variants retain a reduced degree of transactivation potential in transient transfection experiments in HeLa and SKBR3 cells compared with wild-type p53, complementing the results obtained by Pellegata et al, 50 Subler et al 51 and Zhang et al. 52, 53 Transient transfections of expression plasmids driven by viral promoters usually yield high amounts of expressed protein. We studied the dose-response of p53 expression and observed that the extent of wild-type p53-dependent transcription reaches a maximum and decreases again at high levels of p53 (not shown). In contrast, both deletion mutants showed enhanced transactivation with higher amounts of transfected expression plasmids. The nuclear concentrations of p53 were proportional to the amounts of plasmid transfected (data not shown). Our experiments also show that the oligomerisation of p53, through its intrinsic oligomerisation domain or through antibody crosslinking, results in more efficient DNA binding. The binding of the antibody probably results in the stabilisation of protein-DNA complexes by coupling two monomeric proteins. In vitro DNA binding of monomeric p53 can also be achieved by increasing the concentration of the protein in the binding reaction, yielding complexes migrating similarly to wild-type p53-DNA complexes (data not shown). 54 Monomeric p53 variants with a functional DNA binding domain probably aggregate on p53 response elements to form labile DNAprotein complexes. Such complexes are still able to initiate the transcription of genes in vivo. We suggest that the efficiency of DNA binding of p53 is limiting the transcriptional induction and consider this to be the reason for the more effective transactivation by wild-type p53. 19, [54] [55] [56] [57] At high concentrations of wild-type p53 transactivation activity decreased again. p53 functions as a transcription factor itself and contacts members of the basal transcription machinery, such as TBP, the TATA binding protein 58 and the co-activator p300. 59, 60 In combination with sequence-specific DNA binding such interactions are necessary for transactivation of target genes. If high amounts of wild-type p53 are present in the nucleus, sequestration of general transcription factors by p53 can lead to the depletion of such factors and result in squelching. The observation was made only with wild-type p53, but not with monomeric p53 and indicates that limiting transcription factors interact with the carboxy-terminal region of p53. 58 The onset of apoptotic events induced 24-30 h after transfection with the high amount of wildtype p53 could also contribute to the reduced values of luciferase activity.
Although p53⌬326 and p53⌬300 retain some transactivation activity, they were unable to induce apoptosis under our experimental conditions. These results differ from reports in which monomeric or transactivationdeficient p53 variants were shown to induce apoptosis in transiently transfected HeLa cells. 38 It has also been reported that, under certain conditions, p53 can induce apoptosis in the absence of RNA and protein synthesis. 37, 39 These results suggest that monomeric p53 and even transactivation-deficient p53 may have residual apoptotic activity. On the other hand, several groups have shown that the apoptotic activity of p53 is dependent on transcriptional activation 61, 62 and that only wildtype p53 can induce a full apoptotic response in transiently transfected cells or in inducible cell systems. 40, 41 The results presented here, based on two cell lines expressing monomeric p53 under the transcriptional control of tetracycline and unable to induce apoptosis, support the latter conclusions. Since inducible p53 expression in stably transfected cell lines seems somewhat less artificial than transient transfection of cells, we suggest that the induction of apoptosis by monomeric p53 may be due to the particular experimental conditions used.
Our analysis of gene induction in the tetracyclinecontrolled cell clones showed that p53⌬326 was not able to transactivate endogenous p53 target genes, while wildtype p53 caused enhanced expression of the p21/waf1/cip1, mdm2, Gadd45 and bax mRNAs. We did not observe transcriptional repression of the IGF-1R gene in our inducible systems, although repression of the IGF-1R has been proposed as being associated with the induction of apoptosis by wild-type p53. 48, 49 The transactivation of reporter constructs by monomeric p53 is probably limited to situations where overexpression of the monomeric variant coincides with binding to a high affinity response element in the promoter. This is rare under physiological conditions and is the reason why no transactivation by p53⌬326 was observed. While the lack of transcriptional activation of the p21 gene by monomeric p53 results in a G1 checkpoint defect, 36 both loss of transcriptional activation and repression of other target genes might contribute to the deficiency in apoptosis induction. We also examined the potential of monomeric p53 to cause cell cycle arrest in Saos2 or SKBR3 cells upon tetracycline induction. Our results confirmed the observations by Tarunina et al; 36 no cell cycle arrest was found. The interest in monomeric variants of p53 resulted from the possibility of circumventing the dominant-negative effects of mutated p53 molecules found in tumour cells. The usefulness of monomeric variants in a gene therapeutic setting, might be limited, due to the impaired transactivation potential of these molecules. We did not observe dominant-negative effects of the endogenous mutant p53His175 in SKBR3 cells. Wild-type p53 was shown efficiently to transactivate the transcription of luciferase reporter genes as well as endogenous p53 target genes in this cell line. Sequence-specific DNA binding of wild-type p53 was found not to be inhibited and wildtype p53 but not p53⌬326 induced apoptosis in SKBR3 cells after induction of tetracycline-regulated constructs. Induction of apoptosis would be a requirement for the deployment of monomeric variants in a therapeutic context. Efforts to replace the native tetramerisation domain of p53 with engineered oligomerisation domains resulted in proteins that showed higher sequence-specific DNA binding and transactivation activity than monomeric variants of p53. 34, 43 The induction of apoptosis by such chimeric proteins has not yet been systematically evaluated. Post-translational modifications and protein-protein interactions at the carboxyl-terminus of p53 contribute to the regulation of the transcriptional activity of p53. 27, 63 However, we could demonstrate that oligomerisation of p53 is essential for sufficient transcriptional activity and induction of apoptosis.
Materials and methods
Cells and transfections
HeLa cells (derived from a HPV-infected cervical carcinoma), Saos2 cells (derived from an osteosarcoma) and SKBR3 cells (derived from a mammary carcinoma) are human tumour cells which were grown at 37°C in Dulbecco's modified Eagle's medium (DMEM; Boehringer Ingelheim Bioproducts, Germany) supplemented with 10% fetal calf serum (FCS; Gibco BRL, Eggenstein, Germany). The cells were plated 24 h before transfection at 1 × 10 6 cells per 10 cm dish (for luciferase and protein assays) or at 5 × 10 4 cells per well on 12 well dishes supplied with glass coverslips (for immunofluorescence analysis). Cells were transfected by the calcium-phosphate method and the precipitate left on the cells for 6-12 h, after which cells were treated with PBS containing 15% glycerol for 3 min. Luciferase assays were performed 24-30 h later as described elsewhere. 64 Saos2 clones harbouring tetracycline-inducible p53 constructs were obtained after two rounds of stable transfection and selection for hygromycin (Boehringer Mannheim, Mannheim, Germany) and neomycin (Gibco BRL), respectively. Stable clones were maintained in growth medium containing 1 g/ml tetracycline (Sigma, Deisen-hofen, Germany). For induction, cells were seeded in growth medium without tetracycline for the indicated times.
Gel retardation assays and nuclear extracts DNA protein binding reactions were carried out in 20 l volume (per lane) and final concentrations of 50 mm Tris pH 7.9, 50 mm NaCl, 4% glycerol, 2 mm DTT, 0.5 mm MgCl 2 , 0.05% Triton X-100. 2.5 g unspecific competitor DNA (poly d(AT); Boehringer Mannheim) and 1 l BSA per binding reaction. The p53-specific probe was prepared by annealing of the single-stranded oligonucleotides (5′-GATCCCGGGCATGTCCGGGCATGTCCGGG CATGTA3′ and 5′-GATCTACATGCCCGGACATGCC CGGACATGCCCGG-3′) which contain a BC element. 28 The double-stranded oligonucleotides were gel purified and labeled with 32 P by Klenow fill-in reactions. Incubation with antibody PAb1801 (Dianova, Hamburg, Germany) and binding to the labelled DNA were carried out in parallel for 30 min at room temperature. Separation of the complexes was carried out on a 5% polyacrylamide gel in 0.25 × TBE. Nuclear extracts of transiently transfected SKBR3 cells were prepared as described previously. 25 
Plasmids
All p53 expression vectors used in this study were constructed from the pCMX-pL1 65 vector containing the CMV immediate-early promoter/enhancer and human p53 cDNA. Truncated p53 variants, p53⌬326 and p53⌬300 were derived from wild-type cDNA using PCR methods. A cDNA encoding the mutant p53His175 was obtained from P Chène, Novartis, Basel, Switzerland. The pUHD13-1 plasmid contains the tTA transactivator gene and the hygromycin gene, and wild-type p53 or p53⌬326 were cloned into the pUHD10-3 plasmid to allow their conditional expression as described by Gossen and Bujard. 46 The luciferase reporter plasmid pGL2-PG13 contains 13 copies of the RGC p53 binding site, 7 pGL2-mdm2 contains a p53 binding site from intron 1 of the mouse mdm-2 gene 45 linked to a luciferase reporter gene, pGL3-bax contains the p53 response element of the human bax gene promoter. 17 RcCMV-bcl-2 encodes the human bcl-2 gene.
Protein purification BL21(DE3)pLysS-cultures containing the construct pRSETc-p53⌬326 were grown in LB-medium with 100 g/ml ampicillin and 0.6% glucose to OD550 of 0.8-1.0 was attained. Protein expression was induced by addition of 0.2 mm IPTG for 3 h at 37°C. The cultures were harvested by centrifugation at 4400 g. Bacterial pellets were resuspended in 40 ml of ice-cold PBS. The cells were lysed by three steps of freezing in liquid nitrogen and thawing at room temperature. The DNA was sheared by sonication on ice. The lysates were then cleared by centrifugation at 31 000 g in a JA-20 rotor for 30 min at 4°C. The recombinant His-tagged protein was bound to 5 ml of Ni-NTA-agarose (Qiagen, Hilden, Germany) and washed extensively with PBS. The columns were step eluted with PBS containing increasing concentrations of imidazole (50, 100, 200, 300, 400 and 500 mm). p53⌬326 containing fractions were dialysed overnight at 4°C against PBS. The proteins were stored in aliquots at −80°C. As judged by Coomassie blue staining, the purity of the recombinant protein was between 50 and 80%.
Indirect immunofluorescence analysis
Cells were grown on glass coverslips, washed with PBS, fixed in methanol/acetone (1:1) at −20°C for 10 min. Cells were incubated with p53 monoclonal mouse antibody PAb1801 (Dianova) and/or p21 polyclonal rabbit antibody (C-19, Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at 37°C in PBS containing 0.05% Tween 20 (TPBS). The cells were washed with TPBS (three changes within 10 min) and incubated with FITC-conjugated goat anti-mouse IgG (for single IF) or Cy3-conjugated goat anti-mouse IgG plus FITC-conjugated goat anti-rabbit IgG (for Co-IF) for 45 min at 37°C. As indicated, cells were incubated with 50 g/ml propidium iodide in the presence of 0.5 mg/ml RNase A for 15 min at 4°C for DNA staining. After a final wash in TPBS, coverslips were mounted on to slides and viewed under a fluorescence microscope (Zeiss Axiophot; Carl Zeiss, Jena, Germany) for green fluorescence (FITC) at 470 nm and for red fluorescence (Cy3 or PI) at 546 nm.
RNA preparation and RT-PCR analysis
Total RNA was isolated from 10 7 cells grown on 15-cm plates using the RNeasy Kit (Qiagen, Hilden, Germany) as recommended by the manufacturer. For generation of cDNA, 5 g of RNA was heat denatured at 65°C for 10 min. The RT reaction was performed using 0.2 g of d(T)18 at 37°C for 1 h in a total volume of 33 l. Two l (for p53 amplification) or 3 l (others) of the heat denatured (5 min at 90°C) reaction mixture were used for subsequent PCR amplification in 20 l reaction volumes including 10 pmol of each primer. The ␤-actin primer set was included in every reaction to normalise for amplification efficiency and monitor pipetting variations. The following conditions and primer sets were used: ␤-actin (5′ primer: CGCGGGCGACGATGCTC, 3′ primer: TCACGGTTGGCCTTAGGGTTCAGA); p53, 28 cycles at 61°C (5′ primer: CCCCCTCCTGGCCCCTGTCATCTT, 3′ primer: AGGCGGCTCATAGGGCACCACCAC); IGF-1R, 28 cycles at 58.5°C (5′ primer: CACGGCCGCAGA-CACCTACAACA, 3′ primer: AGCGACGGGCAGA GCGATGAT); Gadd45, 28 cycles at 58.5°C (5′ primer: GGATGCCCTGGAGGAAGTGCT, 3′ primer: CGGCC CGGGTTGCTGAC); mdm2, 30 cycles at 53°C (5′ primer: AGGCAGGGGAGAGTGATACAGAT, 3′ primer: AGGGGCAAACTAGATTCCACACT); Bax, 28 cycles at 58.5°C (5′ primer: GATGCGTCCACCAAGAAGC, 3′ primer: TGAGCACTCCCGCCACAA); p21, 28 cycles at 61°C (5′ primer: CGGCCCAGTGGACAGCGAGCAG, 3′ primer: CAGCCGGCGTTTGGAGTGGTAGAA). The complete PCR reactions were separated on 1.5% agarose gels containing 0.01% ethidium bromide and viewed and photographed under UV light. For quantitative analysis bands were scanned and quantified using ImageQuant (Molecular Dynamics, Sunnyvale, CA, USA).
Groner (Gr 536/2-1) and a collaborative grant from Novartis, Basel.
